EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Sapablursen for erythrocytosis control in patients with polycythemia vera

Jeanne M Palmer iD, Jonathan How, Prithviraj Bose iD, Pankit Vachhani iD, Adam J Mead iD, Jonathan Sillar, Aaron T Gerds iD, Angela G Fleischman iD, Caitlin O'Neill iD, Ross Baker iD, Ronald Hoffman, Shiangtung Jung und 6 weitere

Blood · 12.11.2026 · 148 (20) · 2477-2488

DOI: 10.1182/blood.2026033792 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Blood, erschienen am 12.11.2026. Verfasst von Jeanne M Palmer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Polycythemia Vera, Polycythemia, Oligonucleotides, Antisense. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycythemia vera is characterized by erythrocytosis and an increased risk of thrombosis. Sapablursen is an antisense oligonucleotide that suppresses transmembrane serine protease 6, increases hepcidin production, and reduces iron availability for erythropoiesis. IMPRSSION is an ongoing phase 2a, randomized, open-label study in patients with phlebotomy-dependent polycythemia vera. Cohort A (120 or 80 mg) and cohort B (40 mg) received sapablursen subcutaneously once every 4 weeks. The primary efficacy end point was the reduction in phlebotomy frequency from baseline to weeks 17 to 37 in patients who received ≥1 dose. The baseline mean ± standard deviation weekly phlebotomy rate was 0.15 ± 0.07 in cohort A and 0.17 ± 0.07 in cohort B, with reduction by −0.10 (95% confidence interval [CI], −0.13 to −0.07; n = 32; P< .0001) in cohort A and by −0.10 (95% CI, −0.14 to −0.06; n = 17; P = .0001) in cohort B. Sapablursen reduced the median number of phlebotomies from 5.0 at baseline (26 weeks) to 0 in cohort A and 1.5 in cohort B in the efficacy evaluation window (20 weeks). Most adverse events were mild or moderate; anemia and fatigue were most common. The mean change in the myeloproliferative neoplasm–symptom assessment form total symptom score at week 37 was −6.21 points (95% CI, −10.56 to −1.85; P = .0052) in cohort A and −2.71 points in cohort B (95% CI, −8.33 to 2.91; P = .34). Sapablursen reduced phlebotomy need, improved symptoms, and was safe and well tolerated in patients with polycythemia vera. This trial was registered at www.clinicaltrials.gov as NCT05143957.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraPolycythemiaOligonucleotides, AntisenseHumansFemalePhlebotomyMaleMiddle AgedAgedAdultTreatment Outcome

Substanzen

Oligonucleotides, Antisense

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, Mayo Clinic, Phoenix, AZ.
  • Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada.
  • Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL.
  • Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine and National Institute of Health Research, Oxford Biomedical Research Centre, University…
  • Department of Haematology, Calvary Mater Hospital, Waratah, NSW, Australia.

ORCID-Profile: Jeanne M Palmer, Prithviraj Bose, Pankit Vachhani, Adam J Mead, Aaron T Gerds, Angela G Fleischman, Caitlin O'Neill, Ross Baker, Terrance D Barrett, Ruben Mesa

Zitieren

APA

Palmer, J. M., How, J., Bose, P., Vachhani, P., Mead, A. J., Sillar, J., Gerds, A. T., Fleischman, A. G., O'Neill, C., Baker, R., Hoffman, R., Jung, S., Ruckle, J. L., Yousefi, K., Bhanot, S., Barrett, T. D., Mesa, R., & IMPRSSION investigators (2026). Sapablursen for erythrocytosis control in patients with polycythemia vera. Blood, 148(20), 2477-2488. https://doi.org/10.1182/blood.2026033792

Vancouver

Palmer JM, How J, Bose P, Vachhani P, Mead AJ, Sillar J, et al. Sapablursen for erythrocytosis control in patients with polycythemia vera. Blood. 2026;148(20):2477-2488. doi:10.1182/blood.2026033792

BibTeX
@article{Palmer2026,
  author = {Palmer, Jeanne M and How, Jonathan and Bose, Prithviraj and Vachhani, Pankit and Mead, Adam J and Sillar, Jonathan and Gerds, Aaron T and Fleischman, Angela G and O'Neill, Caitlin and Baker, Ross and Hoffman, Ronald and Jung, Shiangtung and Ruckle, Jon L and Yousefi, Keyvan and Bhanot, Sanjay and Barrett, Terrance D and Mesa, Ruben and IMPRSSION investigators, IMPRSSION investigators},
  title = {Sapablursen for erythrocytosis control in patients with polycythemia vera},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {20},
  pages = {2477--2488},
  doi = {10.1182/blood.2026033792}
}
Kostenlos starten →